With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
A new drug for Alzheimer’s was just this month approved by the FDA for use in the United States, in people in the earliest…
UPDATED JULY 3: The Food and Drug Administration has approved Kisunla (generic name donanemab), a new Alzheimer’s drug developed by Eli Lilly. The published data…
Today, the Food and Drug Administration’s (FDA) eleven-person advisory committee unanimously voted, (11-0) that Eli Lilly’s anti-amyloid Alzheimer’s drug donanemab was effective, and that…
The Food and Drug Administration has decided to postpone its decision on the approval of Eli Lilly’s candidate Alzheimer’s drug, donanemab. The delay has…
Neurologists and Alzheimer’s research experts explain the side effect known as ARIA — or brain bleeds — associated with the use of anti-amyloid monoclonal antibody…
Biogen and Eisai’s monoclonal antibody drugs for Alzheimer’s — Aduhelm (now off the market) and Leqembi (fully approved by the FDA in 2023) —…
UPDATE: 3 March 2024, 8:14 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
American pharmaceutical company Eli Lilly announced in May 2023 that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
Alzheimer’s is a notoriously difficult disease to identify with certainty. By the time a patient receives a diagnosis, its pathology in the brain is…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…